Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Perkovic V. et al.
Editor's note
FLOW stopped early for benefit. 3,533 patients with type-2 diabetes and CKD; 24% risk reduction on a composite of kidney failure, ≥50% eGFR loss, and kidney/CV death. The kidney indication GLP-1s have been chasing — landed cleanly.